3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
2
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
5
Neoplasm Metastasis
2
Prostatic Diseases
1
Adenocarcinoma
1
Interventions
Docetaxel
3
regorafenib
2
Doxorubicin
2
trifluridine tipiracil drug combination
1
pegfilgrastim
1
enzalutamide
1
darolutamide
1
bicalutamide
1
apalutamide
1
abiraterone
1
Triptorelin Pamoate
1
Trifluridine
1
Surgical Procedures, Operative
1
Pancreaticoduodenectomy
1
Paclitaxel
1
Nivolumab
1
Irinotecan
1
Cyclophosphamide
1
Cisplatin
1
CP protocol
1
Bevacizumab
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Adenocarcinoma
×
enzalutamide
×
Clear all
NCT06592924
2026-04-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3
Recruiting
830 enrolled